Emerging treatments

Janus kinase (JAK) inhibitors

Several JAK inhibitors are approved by the US Food and Drug Administration (FDA) for atopic dermatitis (e.g., abrocitinib, upadacitinib, and ruxolitinib).[46][47][48]​​​​​​ Ruxolitinib is available as a topical formulation, whereas abrocitinib and upadacitinib are only available as oral formulations. There are also several JAK inhibitors in phase 3 trials including baricitinib, delgocitinib, and PF-04965842.[49][50][51]​​​​​

Dupilumab

Dupilumab, a monoclonal antibody targeting interleukin (IL)-4 and IL-13, is approved in the US and Europe for the treatment of moderate to severe atopic dermatitis, and has been used off-label in the treatment of ACD.[52] However, dupilumab needs to be tested in clinical trials for this indication as the current evidence is based on case reports and retrospective studies.[53][54]​​​

Use of this content is subject to our disclaimer